Predict your next investment

COMPUTER HARDWARE & SERVICES | IT Services / IT Solutions & Software Development
smartfish.com

See what CB Insights has to offer

About Smartfish

Smartfish is focused on helping enterprises optimize business performance and maximize their return on investment through content management applications. In addition, Smartfish specializes in IBM iSeries (AS/400) software solutions.

Smartfish Headquarter Location

228 Deepwater Drive

Chesapeake, Virginia, 23322,

United States

Latest Smartfish News

Global Cancer Cachexia Pipeline Insights Market Report 2020 Featuring AEterna Zentaris, Smartfish AS, Tetra Bio-Pharma, Pfizer, Helsinn Healthcare SA, & Lexicon Pharmaceuticals - ResearchAndMarkets.com

May 13, 2021

The "Cancer Cachexia - Pipeline Insight, 2020," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Cancer Cachexia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Cancer Cachexia Emerging Drugs Chapters This segment of the Cancer Cachexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Cancer Cachexia Emerging Drugs Macimorelin: Aeterna Zentaris Macimorelin stimulates the secretion of growth hormone from the pituitary gland into the circulatory system. Zentaris is conducting a pilot clinical trial of repeated doses of macimorelin to assess safety and efficacy in patients with cancer cachexia. The purpose of this study is to evaluate the safety and efficacy of repeated oral administration of macimorelin at different doses daily for 1 week for the treatment of cancer cachexia. PF- 06946860: Pfizer Pfizer is conducting a phase 1, randomized, double blind, sponsor-open, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of single-dose, subcutaneous administration of PF 06946860 to healthy adult subjects. The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of PF-06946860 in healthy adult subjects following single ascending doses This is the first clinical study of PF-06946860. Cancer Cachexia: Therapeutic Assessment This segment of the report provides insights about the different Cancer Cachexia drugs segregated based on following parameters that define the scope of the report, such as: Major Players in Cancer Cachexia There are approx. 10+ key companies which are developing the therapies for Cancer Cachexia. The companies which have their Cancer Cachexia drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Tetra Bio-Pharma, Helsinn Healthcare etc. Phases Mid-stage products (Phase II and Phase I/II) Early-stage products (Phase I/II and Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Cancer Cachexia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Subcutaneous Small molecules

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Smartfish Patents

Smartfish has filed 3 patents.

The 3 most popular patent topics include:

  • Dietary supplements
  • Colloidal chemistry
  • Food additives
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/24/2017

Dietary supplements, Colloidal chemistry, Food additives, Vitamins, Physical exercise

Application

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

5/24/2017

00/00/0000

00/00/0000

Grant Date

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Related Topics

Dietary supplements, Colloidal chemistry, Food additives, Vitamins, Physical exercise

Subscribe to see more

Subscribe to see more

Status

Application

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.